Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H30N8O7S2 |
| Molecular Weight | 606.674 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 3 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC\C=C(\COC(=O)C1=C(CN=[N+]=[N-])CS[C@@H]2[C@H](NC(=O)C(=N\OC)\C3=CSC(N)=N3)C(=O)N12)C(=O)OCC(C)C
InChI
InChIKey=FHPWLEQQFDSPCU-SVEZEBCVSA-N
InChI=1S/C24H30N8O7S2/c1-5-6-13(22(35)38-8-12(2)3)9-39-23(36)18-14(7-27-31-26)10-40-21-17(20(34)32(18)21)29-19(33)16(30-37-4)15-11-41-24(25)28-15/h6,11-12,17,21H,5,7-10H2,1-4H3,(H2,25,28)(H,29,33)/b13-6-,30-16+/t17-,21-/m1/s1
| Molecular Formula | C24H30N8O7S2 |
| Molecular Weight | 606.674 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 3 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:02:51 GMT 2025
by
admin
on
Wed Apr 02 08:02:51 GMT 2025
|
| Record UNII |
3UK5MH3RJ2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9577440
Created by
admin on Wed Apr 02 08:02:51 GMT 2025 , Edited by admin on Wed Apr 02 08:02:51 GMT 2025
|
PRIMARY | |||
|
124084-44-2
Created by
admin on Wed Apr 02 08:02:51 GMT 2025 , Edited by admin on Wed Apr 02 08:02:51 GMT 2025
|
PRIMARY | |||
|
3UK5MH3RJ2
Created by
admin on Wed Apr 02 08:02:51 GMT 2025 , Edited by admin on Wed Apr 02 08:02:51 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Prevotella, Porphyromonas, Peptostreptococcus, Fusobacterium and Clostridium spp. were susceptible to Ro 40-6890, with few exceptions. Due to its lack of activity against the major pathogens of the Bacteroides fragilis group, Ro 40-6890 does not promise to be of major use in the treatment of infections caused by anaerobes.
|